Use of gene expression signature to predict response to combination chemotherapy in breast cancer clinical subgroups.

Accurate stratification of patients prior to treatment with combination chemotherapy would allow non-responders to receive an alternative treatment in a timely manner and potentially improve clinical outcomes. We describe a 22-gene signature that accurately predicts response to antimitotic combination chemotherapy for breast cancer. This signature was selected in a well characterized system that models a key step disrupted in tumorigenesis: the formation of spatially accurate mammary ductal units by breast epithelial cells.

Click here to view abstract.